“In an initial Phase 1 clinical trial at Massachusetts General Hospital, researchers reported that an experimental CAR T cell therapy produced rapid tumor shrinkage, including one patient whose tumor decreased by nearly 60% within just five days after a single infusion.”
Plain restatementA Phase 1 trial at Massachusetts General Hospital of a CAR T cell therapy for glioblastoma produced rapid tumor reductions on imaging shortly after infusion, and one patient's tumor shrank by nearly 60 percent within five days.
The trial described in this post is real. Researchers at Massachusetts General Hospital ran a Phase 1 study called INCIPIENT, published in the New England Journal of Medicine in April 2024, testing a dual-targeting CAR T cell therapy (CARv3-TEAM-E) delivered directly into the brain in three patients with recurrent glioblastoma. All three patients showed rapid tumor shrinkage on MRI within days of a single infusion. However, the specific claim that "one patient's tumor decreased by nearly 60% within just five days" does not match the published data. In the paper, one patient reached about 60% reduction only by day 69, while the patient who had a response at day 5 had near-complete tumor regression, not 60%. The post also omits an important caveat noted by the researchers themselves: the responses were dramatic but transient, and tumor progression was observed in all three patients over time.
[drifted from the evidence:] In an initial Phase 1 [drifted from the evidence:] clinical trial at Massachusetts General Hospital, [drifted from the evidence:] researchers reported that an experimental CAR T cell therapy produced rapid tumor [drifted from the evidence:] shrinkage, including one [drifted from the evidence:] patient whose tumor [drifted from the evidence:] decreased by nearly 60% within [drifted from the evidence:] just five days [drifted from the evidence:] after a single infusion.
[added by the neutral restatement:] A Phase 1 trial at Massachusetts General Hospital [added by the neutral restatement:] of a CAR T cell therapy [added by the neutral restatement:] for glioblastoma produced rapid tumor [added by the neutral restatement:] reductions on imaging shortly after infusion, and one [added by the neutral restatement:] patient's tumor [added by the neutral restatement:] shrank by nearly 60 [added by the neutral restatement:] percent within five days.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The trial was conducted at Massachusetts General Hospital and is a Phase 1 study.
- The therapy is an experimental CAR T cell therapy (CARv3-TEAM-E).
- It is designed both to target cancer cells directly and to recruit the broader immune response via TEAMs against wild-type EGFR, addressing antigen escape.
- MRI scans showed rapid tumor shrinkage within days.
- The trial involved a small number of patients (three).
- Findings represent an early-stage step in glioblastoma immunotherapy.
- The specific figure "nearly 60% within just five days" does not appear in the NEJM paper. Two patient outcomes appear to have been conflated: - Participant 2 had an 18.5% reduction by day 2, reaching 60.7% only by day 69, not day 5. - Participant 3 had near-complete (much greater than 60%) regression on day 5. - So the number "60%" comes from a different patient at a much later timepoint than "5 days." This is a temporal / attribution distortion. Ironically, it understates the actual day-5 response.
- The post frames the results in largely positive terms without mentioning that the researchers observed tumor progression in these patients , meaning responses were transient in all three.
- Whether the Instagram author intended to describe Participant 2 (60.7% but at day 69) or Participant 3 (near-complete at day 5), since neither exactly matches "nearly 60% at 5 days."
The INCIPIENT trial is designed to evaluate the safety of CARv3-TEAM-E T cells in patients with recurrent GBM. Just days after a single treatment, patients experienced dramatic reductions in their tumors, with one patient achieving near-complete tumor regression. In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule . Per-patient outcomes: - Participant 1, a 74-year-old man, had MRI on day 1 after infusion showing rapid tumor regression, which was confirmed on additional scans over the next two weeks but was ultimately transient. This patient received a second infusion of CARv3-TEAM-E on day 37. Participant 2, a 72-year-old man, had MRI on day 2 showing a decrease in tumor area by 18.5% from the pre-infusion baseline, and by day 69, the decrease reached 60.7%. - Participant 3 experienced a near-complete tumor regression per MRI on day 5 after infusion of 10 x 106 CAR-positive CARv3-TEAM-E T cells, however evidence of recurrence was reported within 1 month of infusion.
Complete reasoning
The reply receipt is formatted for pasting into the thread where the claim is circulating.
Compact share page: verify.trueseeker.com/s/b2a41c4c3fa9/yhCi2Nqm9EV3EJuN479AUnd